Alirocumab tied to improved lipids in diabetes with atherosclerotic

  • Ray KK & al.
  • Cardiovasc Diabetol
  • 9 Nov 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Alirocumab reduces atherogenic cholesterol and LDL particle number (LDL-PN) among people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). 
  • These patients had high non-HDL-cholesterol (HDL-C)/LDL-cholesterol (LDL-C) levels despite maximally tolerated statin treatment.

Study design

  • Analysis of alirocumab efficacy and safety in pooled data from ODYSSEY DM-DYSLIPIDEMIA (n=142) and ODYSSEY DM-INSULIN (n=177), in people with T2D, high LDL-C/non-HDL-C, and established ASCVD despite maximum tolerated statin dose.
  • Funding: Sanofi; Regeneron Pharmaceuticals, Inc.  

Key results

  • Alirocumab was tied to significantly reduced non-HDL-C, LDL-C, apolipoprotein B (ApoB), and LDL-PN from baseline to week 24 vs controls in both studies.
  • At week 24, vs control, a significantly greater proportion achieved:
    • Non-HDL-C
    • LDL-C
    • ApoB
  • For LDL-C
  • Overall, 66.7% (alirocumab) and 67.3% (control) reported treatment-emergent adverse events.
    • These events were serious in 9.5% (drug) vs 8.8% (control) in DM-DYSLIPIDEMIA and 9.0% (drug) vs 9.4% (control) in DM-INSULIN.

Limitations

  • Studies had different designs.